Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  American Heart Journal

• Publication date

  1999-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0002-8703(99)70038-4PMID 10539800
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapy of type 2 diabetes, cardiovascular death, and the UGDP.

  1999cited by this paper
• Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients.

  1997cited by this paper
• Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited.

  1997cited by this paper
• Using admission characteristics to predict short-term mortality from myocardial infarction in elderly patients. Results from the Cooperative Cardiovascular Project.

  1996cited by this paper
• Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration.

  1996cited by this paper
• CARDIOVASCULAR EFFECTS OF ORAL HYPOGLYCAEMIC DRUGS

  1996cited by this paper
• Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators.

  1995cited by this paper
• Oral hypoglycemic agents.

  1989cited by this paper
• Ten-year Follow-up of Subjects with Impaired Glucose Tolerance: Prevention of Diabetes by Tolbutamide and Diet Regulation

  1980cited by this paper
• The crux of the UGDP

  1980cited by this paper
• How good is the statistical evidence against oral hypoglycemic agents

  1979cited by this paper
• Controversy over study of diabetes drugs continues for nearly a decade.

  1979cited by this paper
• How good is the statistical evidence against oral hypoglycemic agents?

  1979cited by this paper
• Vascular complications and long-term administration of oral hypoglycemic agents in patients with diabetes mellitus.

  1978cited by this paper
• A Study of the Effects of Hypoglycemic Agents on Vascular Complications in Patients with Adult-onset Diabetes: VI. Supplementary Report on Nonfatal Events in Patients Treated with Tolbutamide

  1976cited by this paper
• A Summary of Criticisms of the Findings and Conclusions of the University Group Diabetes Program (UGDP)

  1972cited by this paper

• Sulfonylureas and the Risk of Ventricular Arrhythmias Among People with Type 2 Diabetes: A Systematic Review of Observational Studies

  2022influential citation
• Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence.

  2017cites this paper
• Comparative Impact of Hypoglycemic Agents on Severity and Extent of Myocardial Ischemia in Patients With Type 2 Diabetes Mellitus Undergoing Myocardial Perfusion Scintigraphy

  2016cites this paper
• Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer

  2015cites this paper
• Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case–control study

  2014cites this paper
• Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? Yes, They Continue to Serve Us Well!

  2014cites this paper
• Cardiovascular risk factor management of myocardial infarction patients with and without diabetes in the Netherlands between 2002 and 2006: a cross-sectional analysis of baseline data

  2012cites this paper
• Variations in tissue selectivity amongst insulin secretagogues: a systematic review

  2012cites this paper
• Modern antihyperglycemic therapy: safety and efficacy of glimepiride

  2012cites this paper
• Глимепирид в современной гипогликемизирующей терапии: безопасность и эффективность

  2012cites this paper
• Macrovascular effects and safety issues of therapies for type 2 diabetes.

  2011cites this paper
• Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction.

  2010cites this paper
• Outcomes in Diabetic Patients with Acute Myocardial Infarction Impact of Type of Preadmission Sulfonylureas on Mortality and Cardiovascular

  2010cites this paper
• Сердечно-сосудистые последствия современного алгоритма сахароснижающей терапии: «Флорентийская гипотеза»

  2010cites this paper
• Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction.

  2009cites this paper
• Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population‐based follow‐up study

  2009cites this paper
• Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management

  2008cites this paper
• New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.

  2008cites this paper
• Oral Glyburide, But Not Glimepiride, Blocks the Infarct-Size Limiting Effects of Pioglitazone

  2008cites this paper
• The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy

  2008cites this paper
• Острыйкоронарный синдром у больных сахарным диабетом: на пути к Мюнхену-2008

  2008cites this paper
• Sulfonilureas en el tratamiento del paciente con diabetes mellitus tipo 2

  2008cites this paper
• Effect of adenosine triphosphate-sensitive potassium channel inhibitors on coronary metabolic vasodilation.

  2007cites this paper
• Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy.

  2007cites this paper
• Sulfonylureas and the risk of myocardial infarction.

  2006cites this paper
• Three‐year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin

  2006cites this paper
• Risk and Short-Term Prognosis of Myocardial Infarction Among Users of Antidiabetic Drugs

  2006cites this paper
• Association of Diet Alone, Insulin, Sulfonylureas, Metformin, and Thiazolidinediones with the Severity of Coronary Artery Disease in Patients with Diabetes Mellitus

  2006cites this paper
• Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry

  2005cites this paper
• Oral Agents for Type 2 Diabetes: An Update

  2005cites this paper
• Therapie mit oralen Antidiabetika - Besonderheiten bei koronarer Herzerkrankung

  2005cites this paper
• Effect of diabetes mellitus and its treatment on ventricular arrhythmias complicating acute myocardial infarction

  2005cites this paper
• Sulfonylurea Treatment of Type 2 Diabetes Mellitus: Focus on Glimepiride

  2004cites this paper
• Management of diabetes and hyperglycemia in hospitals.

  2004cites this paper
• All‐cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides

  2004cites this paper
• Oral sulfonylureas and CV mortality.

  2004cites this paper
• Sulfonylureas: Basic Aspects and Clinical Uses

  2004cites this paper
• Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?

  2003cites this paper
• Ischemic heart disease in type 2 diabetes.

  2003cites this paper
• Editorial: sulfonylureas differ in effects on ischemic preconditioning--is it time to retire glyburide?

  2003cites this paper
• Sulfonylureas in the prevention of vascular complications: from UKPDS to the ADVANCE study

  2003cites this paper
• Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications.

  2003influential citation
• Stroke Patients With Diabetes Sulfonylurea Drugs Do Not Influence Initial Stroke Severity and In-Hospital Outcome in

  2001cites this paper
• Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone.

  2001cites this paper
• Absence of exacerbation of myocardial stunning in anesthetized dogs treated with KAD-1229, a novel hypoglycemic agent.

  2001cites this paper
• Sulfonylurea Drugs Do Not Influence Initial Stroke Severity and In-Hospital Outcome in Stroke Patients With Diabetes

  2001cites this paper
• Treatment of diabetes mellitus: implications of the use of oral agents.

  1999cites this paper
• Therapy of type 2 diabetes, cardiovascular death, and the UGDP.

  1999cites this paper
• Type 2 diabetes and macrovascular disease: epidemiology and etiology.

  1999cites this paper
• Diabetes and ischemic heart disease.

  1999cites this paper